Skip to main content
. Author manuscript; available in PMC: 2017 Jan 1.
Published in final edited form as: Cancer J. 2016 Jan-Feb;22(1):27–33. doi: 10.1097/PPO.0000000000000166

Table 1. CAR Target Antigens Currently Under Investigation.

CAR Target Antigen Diseases Expression of Normal Tissues Study Phase Toxicity Concerns Other Targeted Therapies
CD19 B-Cell NHLCLLALLMMHL Early pro-B to mature B cell Phase II ongoing B-Cell Aplasia Blinatumomab
CD20 B-Cell NHL B cells from Pre-B cell to B-cell lymphoblast Phase I completed B-Cell Aplasia RituximabOfatumumabObinutuzumabIbrutumomab tiuxetan
CD22 B-Cell NHLALL Mature B cells Phase I ongoing Epratuzumab
CD23 CLL Mature B cells Preclinical data
CD30 HLB-Cell NHL Activated B and T cells, HRS cells Phase I/II ongoing Impaired T cell expansion Brentuximab vedotin
CD33 AML Immature myeloid cells Phase I/II ongoing Myeloablation Gemtuzumab ozogamicin
CD38 MM Plasma cells, T and B lymphocytes, NK cells, myeloid progenitor cells Preclinical Data Myelotoxicity Daratumumab
CD70 NHL Activated Lymphocytes Preclinical Data Impaired cellular immune response
CD123 AMLHL Hematopoietic progenitor cells Phase I ongoing Myeloablation
CD133 AMLALL Hematopoietic progenitor cells Phase I ongoing Myeloablation, off-target effects (also expressed on endothelial progenitor cells, neuronal and glial stem cells)
CD138 MM All plasma cells, epithelium Phase I/II ongoing Mucositis
Kappa Light Chain MMCLLB-Cell NHL Plasma Cells, B Lymphocytes Phase I ongoing
LeY AMLMMMDS Epithelium, early myeloid progenitor cells, multiple different malignancies Phase I ongoing Neutropenia, thrombocytopenia
NKG2D MMAMLMDS NK cells, T cells Phase I ongoing Hypothermic, weight loss, pneumonitis in preclinical models
CS1 MM Plasma Cells, T cells, NK cells, Dendritic cells Preclinical Data Immune deficiency Elotuzumab
BCMA MM Plasma Cells, Mature B cells Phase I ongoing GSK287916
CD44v6 AMLMM Activated T cells, Monocytes, keratinocytes Preclinical Data Epithelial toxicity
ROR1 CLL Pre-B cells, Lymphatic and epithelial malignancies Preclinical Data Off-target effects (expression on adipocytes, lung, pancreas)

NHL: Non-Hodgkin Lymphoma; CLL: Chronic Lymphocytic Leukemia; ALL: Acute Lymphoblastic Leukemia; MM: Multiple Myeloma; HL: Hodgkin Lymphoma; AML: Acute Myeloid Leukemia; MDS: Myelodysplastic Syndrome; HRS: Hodgkin Reed-Sternberg; NK: Natural Killer